

Rheumatoid Arthritis (RA) - Pipeline Insight, 2021

<https://marketpublishers.com/r/R280BC7CBC67EN.html>

Date: July 2021

Pages: 120

Price: US\$ 3,000.00 (Single User License)

ID: R280BC7CBC67EN

Abstracts

This report can be delivered to the clients within 7-10 Business Days

DelveInsight's, "Rheumatoid Arthritis (RA) - Pipeline Insight, 2021," report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Rheumatoid Arthritis (RA) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Rheumatoid Arthritis (RA) Understanding

Rheumatoid Arthritis (RA): Overview

Rheumatoid arthritis (RA) is a chronic, progressive, and disabling autoimmune disease. Rheumatoid Arthritis (RA) mainly attacks the joints, usually many joints at once. RA commonly affects joints in the hands, wrists, and knees. Signs and symptoms of RA include pain or aching in more than one joint, stiffness in more than one joint, tenderness and swelling in more than one joint, weight loss, weakness, fever, and/or fatigue or tiredness. Rheumatoid Arthritis (RA) is diagnosed by reviewing symptoms, conducting a physical examination, and doing X-rays and lab tests. Treatment for Rheumatoid Arthritis (RA) usually includes the use of medications that slow disease and prevent joint deformity, called disease-modifying antirheumatic drugs (DMARDs); biological response modifiers (biologicals) are medications that are an effective second-

line treatment.

'Rheumatoid Arthritis (RA) - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Rheumatoid Arthritis (RA) pipeline landscape is provided which includes the disease overview and Rheumatoid Arthritis (RA) treatment guidelines. The assessment part of the report embraces, in depth Rheumatoid Arthritis (RA) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Rheumatoid Arthritis (RA) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Rheumatoid Arthritis (RA) R&D. The therapies under development are focused on novel approaches to treat/improve Rheumatoid Arthritis (RA).

Rheumatoid Arthritis (RA) Emerging Drugs Chapters

This segment of the Rheumatoid Arthritis (RA) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Rheumatoid Arthritis (RA) Emerging Drugs

Ozoralizumab: Taisho Pharmaceutical

Ozoralizumab (ATN-103) is a trivalent humanized low molecular weight compound that combines two anti-TNF α NANOBODY $\text{\textcircled{R}}$ VHHs and one anti-serum albumin NANOBODY $\text{\textcircled{R}}$ VHH. Ozoralizumab is about a quarter of the size of conventional IgG antibodies. Ozoralizumab binds to two subunits of TNF α and potently neutralizes its action. Ozoralizumab, initially discovered by Ablynx. In March 2021, Taisho announced

that it submitted an application for approval to manufacture and market the anti-TNF? NANOBODY® therapeutic (generic name: ozoralizumab) to the Ministry of Health, Labour and Welfare for rheumatoid arthritis (RA).

ABX464: Abivax

ABX464 is an oral, first-in-class, small molecule that binds to the RNA cap binding protein (CBC 80/20) complex which sits at the 5' end of every RNA molecule and enhances pre-mRNA splicing. The drug is in Phase II clinical studies for the treatment of Rheumatoid Arthritis (RA).

Further product details are provided in the report.....

Rheumatoid Arthritis (RA): Therapeutic Assessment

This segment of the report provides insights about the different Rheumatoid Arthritis (RA) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Rheumatoid Arthritis (RA)

There are approx. 100+ key companies which are developing the therapies for Rheumatoid Arthritis (RA). The companies which have their Rheumatoid Arthritis (RA) drug candidates in the most advanced stage, i.e. Preregistration include, Taisho Pharmaceutical.

Phases

DelveInsight's report covers around 100+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Rheumatoid Arthritis (RA) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravitreal

Subretinal

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Rheumatoid Arthritis (RA): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Rheumatoid Arthritis (RA) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Rheumatoid Arthritis (RA) drugs.

Rheumatoid Arthritis (RA) Report Insights

- Rheumatoid Arthritis (RA) Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Rheumatoid Arthritis (RA) Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Rheumatoid Arthritis (RA) drugs?

How many Rheumatoid Arthritis (RA) drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Rheumatoid Arthritis (RA)?

What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Rheumatoid Arthritis (RA) therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Rheumatoid Arthritis (RA) and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Abivax

Kymera Therapeutics

Akari Therapeutics

Sierra Oncology

Neutrolis Therapeutics

Centivax

Taisho

Hope Biosciences

UCB

Galmed Pharmaceuticals

Celon Pharma

Jiangsu Hengrui Medicine Co.

Cyxone

Oryn Therapeutics

Key Products

ABX464

KT 474

Nomacopan

Momelotinib

NTR 441

Anti-CXCR5 antibody

Ozoralizumab

HB adMSCs

Olokizumab

Amilo-5MER

CPL-409116

SHR 0302

Rabeximod

ORTD 1

Contents

Introduction

Executive Summary

Rheumatoid Arthritis (RA): Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Rheumatoid Arthritis (RA) – DelveInsight's Analytical Perspective

Late Stage Products (Phase III)

Comparative Analysis

SHR 0302: Jiangsu Hengrui Medicine Co.

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

ABX464: Abivax

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

Amilo-5MER: Galmed Pharmaceuticals

Product Description

Research and Development

Product Development Activities
Drug profiles in the detailed report.....
Preclinical/Discovery Stage Products
 Comparative Analysis
KT 474: Kymera Therapeutics
 Product Description
 Research and Development
 Product Development Activities
Drug profiles in the detailed report.....
Inactive Products
 Comparative Analysis
Rheumatoid Arthritis (RA) Key Companies
Rheumatoid Arthritis (RA) Key Products
Rheumatoid Arthritis (RA)- Unmet Needs
Rheumatoid Arthritis (RA)- Market Drivers and Barriers
Rheumatoid Arthritis (RA)- Future Perspectives and Conclusion
Rheumatoid Arthritis (RA) Analyst Views
Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Rheumatoid Arthritis (RA)
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Rheumatoid Arthritis (RA)
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Rheumatoid Arthritis (RA) - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/R280BC7CBC67EN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R280BC7CBC67EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970